Cambodia’s Health Landscape & Taj Pharma’s Partnership Vision (2025-2026)

Cambodia has achieved notable public health gains over the past two decades—especially on malaria, immunization, and tuberculosis—while contending with a fast-rising burden of noncommunicable diseases (NCDs), recurring dengue surges, and persistent out‑of‑pocket (OOP) spending that strains households. In 2024–2025, policy attention remains fixed on Universal Health Coverage (UHC), strengthening procurement and supply chains, and safeguarding the poor through Health Equity Funds (HEF).

Taj Pharma India proposes a comprehensive collaboration to serve Cambodia’s people by:

• Supplying WHO‑cGMP‑compliant essential medicines aligned with Cambodia’s National Essential Medicines List (EML, 10th Edition),
• Supporting tender participation (national and donor‑funded),
• Partnering in school health and primary care programs (deworming, ORS/Zinc, WASH‑linked hygiene),
• Co‑creating targeted access initiatives for poor and vulnerable populations in alignment with HEF,
• Offering knowledge transfer, pharmacovigilance support, and robust post‑marketing quality assurance.

Cambodia’s Health Profile: At a Glance

Epidemiological transition. Cambodia is moving from a communicable‑disease‑dominant profile toward an NCD‑heavy burden (cardiovascular disease, stroke, diabetes, chronic liver disease), while infectious threats (dengue, TB) and public health emergencies still require strong, agile response. Road injuries and trauma remain significant causes of death and disability.

Key achievements.

• Malaria: Near‑elimination trajectory, sustained multi‑year zero malaria deaths, and very low case counts in recent years.
• TB: Long‑term declines in incidence and mortality, reflecting policy and programmatic gains.
• Maternal/child health: Improved outcomes with continued need for quality, equity, and resilient service delivery.

Continuing challenges.

• NCD surge: Hypertension, diabetes, dyslipidemia, and liver disease require chronic‑care models, reliable medicine availability, and patient education.
• Vector‑borne disease: Dengue remains cyclical and climate‑sensitive; stockpiles of supportive care medicines and fluids are vital.
• Financial risk protection: OOP spending remains high; scaling HEF and social health protection instruments is a priority.
• Supply chain and quality: Continued vigilance against substandard/falsified products, adherence to EML, and strong GDP‑compliant distribution.

Health Financing & Policy Direction

• Budget context: Cambodia’s health budget has faced tight trade‑offs amid broader fiscal priorities. Discussions on expanding fiscal space for health and improving purchasing efficiency are ongoing.
• UHC pathway: The national roadmap emphasizes stronger primary care, digitized health information, improved workforce training, and expanded social health protection (HEF, NSSF), with an emphasis on value‑for‑money and equitable coverage.
• Procurement & supply: The Ministry of Health’s Central Medical Store (CMS) centrally procures EML medicines and distributes to public facilities; donor‑funded mechanisms (e.g., Global Fund, World Bank‑financed projects) complement national procurement. Strengthening quantification, LMIS, pharmacovigilance, and cold‑chain/logistics continues to be a priority.

Priority Disease Areas & Medicine Needs

1) Infectious & Vector‑Borne Diseases

• Malaria: Case management and surveillance for elimination; continued readiness for P. falciparum containment. Medicines: artemisinin‑based combination therapies (ACTs), primaquine (per national guidelines), supportive antipyretics, IV fluids.
• Dengue: Seasonal surges demand rapid access to supportive therapy (paracetamol, oral/IV rehydration, colloids/crystalloids per clinical guidance) and diagnostics.
• Tuberculosis: First‑line TB medicines (HRZE combinations), ancillary products (pyridoxine), and lab consumables. Integration with HIV services remains important.
• Diarrhoeal diseases/enteric infections: ORS + zinc standard of care; targeted antibiotics only per guideline‑indicated cases.

2) Noncommunicable Diseases (NCDs)

• Cardiovascular & metabolic: Antihypertensives (ACEIs/ARBs, CCBs, thiazide diuretics), statins, antiplatelets, oral hypoglycemics/insulin, and diabetes supplies.
• Chronic respiratory: Inhaled bronchodilators/corticosteroids; spacers; nebulization solutions.
• Liver disease: Medicines addressing complications (e.g., diuretics for ascites; lactulose for encephalopathy) and viral hepatitis programs.
• Cancer care (foundational): Essential oncology generics (per EML prioritization) and antiemetics, analgesics, and adjuvant medicines.

3) Maternal, Newborn & Child Health (MNCH)

• Uterotonics (oxytocin), magnesium sulfate, antenatal micronutrients (iron–folate), neonatal antibiotics, vitamin K, chlorhexidine for cord care (as per national policy), and pediatric formulations (dispersible tablets, oral liquids).

4) Emergency & Critical Care

• Broad‑spectrum antibiotics (stewardship‑aligned), analgesics, anesthetics and neuromuscular blockers (operating theatre/ICU), IV fluids/electrolytes, antiseptics/disinfectants, emergency obstetric supplies.

Taj Pharma’s Cambodia‑Aligned Portfolio (Illustrative)

Manufactured under WHO‑cGMP, GMP, GLP; EU‑GMP and PIC/s aligned facilities; ISO 9001:2018; SGS audits. Portfolio mapped to Cambodia’s EML therapeutic areas.

Anti‑infectives

• Beta‑lactams, macrolides, quinolones, nitroimidazoles; anti‑TB fixed‑dose combinations; antiparasitics (albendazole/mebendazole); antimalarials (policy‑compliant ACT co‑formulations; primaquine*).
• Antiseptics/disinfectants: Chlorhexidine gluconate solutions (1%/4% topical), povidone‑iodine line.

Public health essentials

• ORS (WHO formula; flavored variants); zinc dispersible tablets; vitamin/mineral supplements; deworming tablets; topical dermatology (e.g., coal tar/zinc oxide ointments as indicated).

ICU/OT and hospital injectables

• Dexamethasone sodium phosphate; heparin sodium (various strengths); rocuronium bromide; metoclopramide; omeprazole sodium for injection; IV antibiotics.

NCD & chronic care

• Antihypertensives; statins; antiplatelets; metformin and other oral antihyperglycemics; insulin program support (where applicable); inhalation therapies.

Note: All antimalarial offerings will adhere strictly to Cambodia’s national treatment guidelines, including G6PD considerations for primaquine. Registration status and dossier pathways can be confirmed jointly with MoH/NHQC; Taj Pharma maintains full CTD/ACTD dossiers and stability data to expedite regulatory review.

Engagement Tracks for Cambodia

A) Government Tenders & Framework Agreements

• Central Medical Store (CMS): Participate in national EML procurement cycles; align pack sizes, Khmer/English labeling, and pharmacovigilance reporting. Offer competitive pricing with framework‑level volume commitments.
• Donor‑funded procurement: Align with Global Fund/UN mechanisms for TB/HIV/malaria and World Bank‑financed health operations. Ensure traceability (GS1 barcoding where requested), QA/QC batch documentation, and on‑time delivery.
• e‑procurement readiness: Support electronic tender submissions and digital compliance documentation (GMP, CoPP, CoA, stability, bioequivalence/biowaiver, PILs, artworks).

B) School Health & Preventive Care Partnerships

• Deworming & WASH: Provide mebendazole/albendazole with teacher‑friendly dosing guides; co‑develop ORS+Zinc school kits; support menstrual hygiene education materials; deliver safe‑use training.
• Nutrition & oral health: Micronutrient supplementation; toothbrush/toothpaste kits (via partners); handwashing promotion collateral in Khmer.

C) Pro‑Poor Access (HEF‑Aligned)

• Facility support: Reserved inventory buffers for HEF facilities; emergency replenishment protocols.
• Affordability: Tiered pricing for HEF facilities and poor patient programs; sample donation for priority wards; patient assistance vouchers where permitted.
• Data & pharmacovigilance: Simple adverse event reporting; periodic utilization dashboards co‑reviewed with facility managers and MoH.

D) Capacity Building & Quality Systems

• Pharmacy practice: Rational use, antimicrobial stewardship, and stock management (FEFO); AMR awareness campaigns.
• Clinical training: Protocol refreshers for ORS+Zinc, pediatric dosing, sepsis bundles, safe anesthesia.
• Supply‑chain: Forecasting, LMIS support, barcoding, and cold chain validation.

Regulatory & Technical Readiness

• Dossiers: ACTD/CTD formats; stability in Climatic Zone IVb; complete CoAs; validated analytical methods; pilot/scale batch records (BMR/BPR); bioequivalence/bio‑waiver packages where applicable.
• Labeling & artwork: Khmer/English artworks integrating MoH requirements (generic name prominence, batch/expiry, storage, warnings, QR/GS1 if required), with Taj’s serialization/traceability options.
• Quality Assurance: Full batch release package: MFR, QC reports, process validation/cleaning validation, OOS/OOT procedures, change control history.

Social Impact Commitments for Cambodia

• “First 1,000 Days”: Prioritize MNCH supply (iron–folate, oxytocin, zinc, ORS, chlorhexidine for cord care) and ensure rural access via CMS channels.
• Dengue preparedness: Pre‑season buffer stocks (paracetamol, fluids, pediatric syrups) and rapid replenishment to affected provinces.
• Road‑injury response: Trauma‑care essentials (IV fluids, analgesia, antibiotics) and safe‑anesthesia packs for referral hospitals.
• HEF support: Outcome‑linked discounts for facilities with high HEF caseloads; periodic donations for indigent wards.

Taj Pharma Vision & Mission for Cambodia’s Healthcare

Vision: Every Cambodian—especially children, mothers, and the poor—can access safe, effective, and affordable essential medicines, everywhere and every time they’re needed.

Mission: To partner with Cambodia’s Ministry of Health, CMS, hospitals, and development partners to:

1. Secure uninterrupted availability of EML‑aligned medicines with verifiable quality,
2. Reduce catastrophic OOP spending by lowering acquis